Posted on February 8th, 2012 by Health News
Short-term use of the antibiotic cefpodoxime for the treatment of women with uncomplicated cystitis (bladder infection) did not meet criteria for noninferiority for achieving clinical cure compared with ciprofloxacin, a drug in the fluoroquinolone class of antibiotics for which there have been concerns about overuse and a resulting increase in resistance rates, according to a [...]
No Comments »
Filed under: Pharmacy News
Posted on February 8th, 2012 by Health News
Following a total joint replacement, anticoagulation (blood thinning) drugs can prevent Deep Vein Thrombosis (DVT), a blood clot deep within the extremities, or a pulmonary embolism (PE), a complication that causes a blood clot to move to the lungs.
No Comments »
Filed under: Pharmacy News
Posted on February 8th, 2012 by Health News
Treatment with three relatively new “targeted” cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that the risk remains low, but should be taken into account by physicians and patients.
No Comments »
Filed under: Pharmacy News
Posted on February 8th, 2012 by Health News
It has long been known that psychostimulant drugs have the paradoxical effect of reducing hyperactivity. [Psychostimulant drugs include methylphenidate - known by the trade names Ritalin, Concerta, and Methylin - and methamphetamine]. Since the mid-1950s, millions of children and adults have been prescribed stimulant medications to control attention deficit hyperactivity disorder.
No Comments »
Filed under: Pharmacy News
Posted on February 8th, 2012 by Health News
With the new year came many drug recalls. In the first six weeks of 2012, there were at least 13 drug-related recalls. Some were due to bacterial contamination. Eight distinct bacterial contaminants were identified in one over-the-counter product.
No Comments »
Filed under: Pharmacy News
Posted on February 8th, 2012 by Health News
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application for pertuzumab and granted Priority Review.
No Comments »
Filed under: Pharmacy News
Posted on February 8th, 2012 by Health News
An endocrine hormone used in clinical trials as an anti-obesity and anti-diabetes drug causes significant and rapid bone loss in mice, raising concerns about its safe use, UT Southwestern Medical Center researchers have shown.
No Comments »
Filed under: Pharmacy News
Posted on February 8th, 2012 by Health News
Sanofi announced today that the U.S. Food and Drug Administration (FDA) has approved Sklice® (ivermectin) lotion, 0.5% for the topical treatment of head lice, in patients 6 months of age and older. Effective and well-tolerated, Sklice Lotion treats lice in most patients with a single 10-minute application of the lotion, without nit combing.
No Comments »
Filed under: Pharmacy News
Posted on February 8th, 2012 by Health News
U.S. health regulators, the Food and Drugs Administration (FDA) has granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. Pertuzumab approval decision is due by June 8th this year. It could be used with Herceptin in HER2-positive patients. This [...]
No Comments »
Filed under: Pharmacy News
Posted on February 7th, 2012 by Health News
SAN FRANCISCO (MedPage Today) — Metastatic kidney cancer patients deemed ineligible for targeted therapy clinical trials, but who still received the trial treatment protocol, faced a higher mortality risk, researchers found.
No Comments »
Filed under: General Health News
